Continued Five Year Benefit of Venetoclax Plus Rituxamab To Treat Chronic Lymphocytic Leukemia
John Hayslip, MD, executive medical director at AbbVie Pharmaceuticals discusses the latest data from the MURANO study presented at ASH 2020.
The MURANO study compared the safety and efficacy of 6 months of treatment with venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Results from that study published in 2018 in the New England Journal of Medicine showed venetoclax plus rituximab to be far superior to bendamustine plus rituximab. More specifically, at the 2-year mark, median PFS was not reached in the venetoclaxโrituximab group compared to a median of 17 months in the bendamustine plus rituximab group.
At ASH 2020, new 5 year follow up data was presented and continued to show the superiority of venetoclax plus rituximab. The new data showed Median PFS was 53.6 months in the venetoclax plus rituximab group compared to 17.0 months in the bendamustine plus rituximab group.
CLL is a rare blood cancer involving the build-up of lymphocytes in bone marrow, lymph nodes, and blood. The disease is considered treatable, but relapse is very common.
-
Category
No comments found